What is the recommended treatment for a patient with a positive direct Coombs test, low platelet count, and low hemoglobin suggestive of Evans syndrome?

Management of Evans Syndrome: Positive Direct Coombs Test with Thrombocytopenia and Anemia

For a patient presenting with positive direct Coombs test, low platelets, and low hemoglobin suggestive of Evans syndrome, initiate aggressive first-line therapy with high-dose corticosteroids (prednisone 1-2 mg/kg/day) combined with intravenous immunoglobulin (IVIg 1 g/kg), treating both the autoimmune hemolytic anemia and immune thrombocytopenia simultaneously. 1

Initial Diagnostic Workup

Before initiating treatment, confirm the diagnosis and exclude secondary causes:

• Perform extensive laboratory evaluation including complete blood count with reticulocyte count, lactate dehydrogenase, haptoglobin, indirect bilirubin, and peripheral blood smear to document hemolysis 1, 2
• Test for infectious triggers: HIV, hepatitis C virus (HCV), and Helicobacter pylori (via urea breath test or stool antigen) 3, 4, 1
• Screen for underlying conditions: antinuclear antibodies, antiphospholipid antibodies, lymphoproliferative disorders via CT scan, and consider bone marrow evaluation to exclude malignancy 1
• Measure ADAMTS-13 activity and inhibitors if the patient shows refractoriness to initial corticosteroids, as concurrent thrombotic thrombocytopenic purpura can mimic Evans syndrome 5

The diagnosis of Evans syndrome is one of exclusion—you must rule out systemic lupus erythematosus, lymphoproliferative diseases, and drug-induced cytopenias before confirming primary Evans syndrome. 1, 6

First-Line Treatment Strategy

Corticosteroid Therapy

Administer prednisone at 1-2 mg/kg/day (or equivalent methylprednisolone if intravenous route needed) as the cornerstone of initial therapy. 1, 6 The 2024 consensus recommendations emphasize that Evans syndrome requires more aggressive and prolonged corticosteroid courses than isolated ITP, given the dual autoimmune process. 1

• For autoimmune hemolytic anemia component: maintain higher corticosteroid doses for longer duration (typically 4-6 weeks before tapering) 1
• For immune thrombocytopenia component: standard ITP guidelines suggest treatment when platelets <30 × 10⁹/L, but in Evans syndrome treat regardless of platelet count given the hemolytic component 3, 4

Intravenous Immunoglobulin

Add IVIg 1 g/kg as a single dose to corticosteroids in Evans syndrome, particularly when rapid platelet rise is needed or when significant bleeding risk exists. 3, 4, 1 The combination provides faster response than corticosteroids alone. 3

IVIg emerged as the primary treatment regimen in systematic reviews of Evans syndrome cases, administered in 13 of 16 reported cases with generally favorable responses. 7

Critical Pitfall: Avoid Anti-D Immunoglobulin

Do not use anti-D therapy in patients with hemoglobin decreased due to bleeding or with evidence of autoimmune hemolysis. 3 This is a critical contraindication specific to Evans syndrome—anti-D can worsen hemolysis in patients with concurrent autoimmune hemolytic anemia. 3

Second-Line Treatment Options

If the patient fails to respond adequately to corticosteroids plus IVIg within 2-4 weeks, or experiences early relapse during steroid taper:

Rituximab (Preferred Second-Line)

Rituximab 375 mg/m² weekly for 4 weeks is strongly recommended as second-line therapy for Evans syndrome, particularly in the following scenarios: 1, 6

• Warm-type autoimmune hemolytic anemia with inadequate response to corticosteroids 1
• Cold-type autoimmune hemolytic anemia (where rituximab should be considered even as first-line) 1
• Patients with antiphospholipid antibodies or previous thrombotic events 1
• Associated lymphoproliferative disorders (consider rituximab plus bendamustine combination) 1

However, avoid rituximab in patients with immunodeficiency or severe active infections, as it causes profound B-cell depletion. 1 The 2024 consensus panel specifically discouraged rituximab in these populations. 1

Rituximab induces remission in the majority of Evans syndrome patients, though responses are often sustained for <12 months, requiring vigilant monitoring for relapse. 6

Immunosuppressive Agents

For patients who cannot receive rituximab or have contraindications:

• Cyclosporine or mycophenolate mofetil are recommended immunosuppressive options 6
• These agents have been moved to third-line or further-line treatment in recent consensus recommendations, behind rituximab 1
• Combination therapy (e.g., cyclosporine plus danazol) may be considered for refractory cases 6

Thrombopoietin Receptor Agonists

TPO-RAs (romiplostim or eltrombopag) are recommended for the thrombocytopenic component if it persists despite treatment of the hemolytic anemia, particularly in chronic cases (>12 months duration). 4, 1

• Use TPO-RAs when platelet count remains <30 × 10⁹/L despite other therapies 4
• Particularly valuable for patients with previous grade 4 infections where rituximab is contraindicated 1
• Fostamatinib is recommended as third-line or further-line treatment, and suggested as second-line for patients with previous thrombotic events 1

Splenectomy Considerations

Splenectomy should be approached with extreme caution in Evans syndrome and is generally discouraged compared to isolated ITP. 1, 6

• Long-term remissions after splenectomy are less frequent in Evans syndrome than in uncomplicated ITP 6
• The 2024 consensus panel discouraged splenectomy for patients with immunodeficiency or severe infections 1
• If considered, delay splenectomy for at least 12 months unless disease is severe and refractory to all other measures 3
• Both laparoscopic and open approaches offer similar efficacy when surgery is necessary 3

Adjunctive and Supportive Therapies

For Inadequate Reticulocyte Response

Administer recombinant erythropoietin when autoimmune hemolytic anemia presents with inappropriately low reticulocyte counts, suggesting concurrent bone marrow suppression. 1

For Cold Agglutinin Disease

Use the complement inhibitor sutimlimab for relapsed cold-type autoimmune hemolytic anemia in Evans syndrome. 1

Transfusion Strategy

• Red blood cell transfusions: Administer when hemoglobin drops to symptomatic levels or <7 g/dL, using least incompatible units 1
• Platelet transfusions: Reserve for active bleeding or pre-procedure prophylaxis when platelets <10 × 10⁹/L; avoid routine prophylactic transfusions 1

Thromboprophylaxis

Provide thrombotic prophylaxis in hospitalized patients with Evans syndrome, as they face dual risk from both the disease and corticosteroid therapy. 1 Consider low-molecular-weight heparin unless platelets <20 × 10⁹/L with active bleeding.

Antibiotic Prophylaxis

Initiate Pneumocystis jirovecii prophylaxis (trimethoprim-sulfamethoxazole or alternative) for all patients receiving prolonged high-dose corticosteroids plus additional immunosuppression. 1

Treatment of Refractory Evans Syndrome

For patients failing multiple lines of therapy:

• Stem cell transplantation (allogeneic preferred over autologous) offers the only chance of long-term cure in very severe, refractory cases 6
• Reduced-intensity conditioning regimens have shown success and should be considered for younger patients in the context of clinical trials 6
• Both approaches carry significant risks of morbidity and transplant-related mortality 6

Monitoring and Follow-Up

• Weekly complete blood counts during initial treatment phase to assess response of both hemoglobin and platelet count 1
• Monitor for infectious complications given intensive immunosuppression—maintain high index of suspicion for opportunistic infections 1
• Assess for thrombotic events, particularly in patients with antiphospholipid antibodies 1
• Long-term surveillance for relapse, which is frequent in Evans syndrome, occurring in the majority of patients 6

Special Clinical Scenarios

COVID-19-Associated Evans Syndrome

Recent case series document Evans syndrome developing 5 days to 3 weeks following COVID-19 infection or mean 9 days post-vaccination. 7 Early initiation of corticosteroids plus IVIg appears effective as first-line therapy in these cases, with most patients achieving at least partial response. 7

Drug-Induced Evans Syndrome

Immune checkpoint inhibitors (atezolizumab plus bevacizumab) can trigger Evans syndrome as an immune-related adverse event. 8 Discontinue the offending agent and initiate high-dose corticosteroids immediately. 8